Content area

|
|

Glukagonlignende peptid 1-receptoragonisten semaglutid

Forfatter(e)
Amalie Dyhrberg Boje1, Christian Rimer Juhl1, Signe Sørensen Torekov1 & Sten Madsbad2 1) Biomedicinsk Institut, Det Sundhedsvidenskabelige Fakultet, Københavns Universitet 2) Endokrionologisk Afdeling,
Hvidovre Hospital

Ugeskr Læger 2019;181:V03190155
Reference: 
Ugeskr Læger 2019;181:V03190155
Blad nummer: 

Amalie Dyhrberg Boje, Christian Rimer Juhl,
Signe Sørensen Torekov & Sten Madsbad:

The glucagon-like peptide-1 receptor-agonist semaglutide

Ugeskr Læger 2019;181:V03190155

Semaglutide is a glucagon-like peptide-1 receptor-agonist (GLP-1 RA), which is injected subcutaneously once a week for treatment of Type 2 diabetes. In this review, the present results of semaglutide treatment are presented. Semaglutide has been evaluated in more than 8,000 patients across the spectrum of Type 2 diabetes. Trials with semaglutide have demonstrated superiority with sustained improved glycaemic control and weight loss compared to oral antidiabetic agents, other GLP-1 RAs and basalinsulin. In addition, semaglutide significantly decreased the occurrence of cardiovascular events compared with standard pharmacological diabetic treatment combined with placebo.

Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Hanne Hulgaard | 19/04
1 Kommentar
af Henrik Isaksen Dietz | 19/04
2 kommentarer
af Bjørn Asser Hansen | 17/04
1 Kommentar
af Christian Emil Møller | 17/04
8 kommentarer
af Søren Bache | 17/04
3 kommentarer
af Kristina Herbst | 17/04
2 kommentarer